During the past decade, St. Johanns LK conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Johanns LK" #1 collaborator was "Hoffmann-La Roche" with 1 trials as a collaborator and "Schering-Plough" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "St. Johanns LK" are "B-cell Chronic Lymphocytic Leukemia" (1 trials), "Diffuse Large B-Cell Lymphoma (DLBCL)" (1 trials) and "Follicular NHL Grade 3b" (1 trials). Many other conditions were trialed in "St. Johanns LK" in a lesser frequency.

Most popular intervention types in "St. Johanns LK" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Alemtuzumab" (1 trials), "Fludarabine phosphate" (1 trials) and "Rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Johanns LK" are 2 trials for "All" genders.

Currently, there are NaN active trials in "St. Johanns LK". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in St. Johanns LK, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in St. Johanns LK, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".